As the first quarter of 2026 draws to a close, the METAvivor advocacy team is intensifying its efforts on Capitol Hill, balancing the complexities of federal appropriations with the strategic expansion of its grassroots infrastructure.
The mission to secure critical funding for metastatic breast cancer (MBC) research has entered a high-stakes phase. Following the conclusion of the third annual "GroundSwell" virtual advocacy event, the organization is pivoting toward a rigorous campaign for Fiscal Year (FY) 2027 appropriations, while simultaneously navigating a volatile political climate in Washington, D.C.
The Landscape of Federal Appropriations: FY 2027 and Beyond
The federal budget cycle is a perennial challenge for patient advocacy groups, but the current atmosphere is particularly fraught with uncertainty. As the House and Senate prepare for the release of the President’s Budget—expected in the final week of March—METAvivor has already begun active outreach to lawmakers.
The $150 Million Priority
At the heart of METAvivor’s legislative agenda is the Department of Defense (DoD) Breast Cancer Research Program (BCRP). The organization has formally requested a $150 million allocation for the program, which represents a $5 million increase over FY 2026 levels and a strategic return to the funding benchmarks established in FY 2024.
METAvivor leadership emphasizes that this is not merely a request for increased dollars; it is a request for the prioritization of metastatic research. By leveraging coalition partnerships with other patient, provider, and research advocacy groups, METAvivor aims to present a unified front to appropriators, arguing that stable, robust funding is the only path to meaningful breakthroughs in survival rates.
The DHS Stalemate and Fiscal Contagion
While the focus remains on health-related appropriations, the broader political environment remains paralyzed by the unfinished business of the FY 2026 budget. A standoff regarding the Department of Homeland Security (DHS) has resulted in a partial government shutdown of several agencies, including the Coast Guard, the Secret Service, and the TSA.
Although the Immigration and Customs Enforcement (ICE) agency—a focal point of the partisan divide—is currently funded through previous legislative actions, the overall impasse has created a toxic environment for future budget negotiations. Analysts suggest that the combination of this ongoing stalemate and the escalating fiscal demands of international conflicts, specifically the war in Iran, will likely compress the timeline and harden the tone of the upcoming FY 2027 debates.
NIH Oversight and the Future of Grant Making
On March 17, the House Appropriations Committee’s Subcommittee on Labor, Health and Human Services, and Education (LHHS) convened a critical oversight hearing featuring NIH Director Dr. Jay Bhattacharya. The hearing served as a barometer for the current administration’s health research priorities.
The Promise of Acceleration
Dr. Bhattacharya, who has also been tapped for the role of Acting CDC Director, delivered a clear message to the committee: the NIH is committed to clearing the backlog of grant funding by the end of FY 2026. He highlighted that the National Cancer Institute (NCI) is actively accelerating the grant approval process to meet this deadline. Furthermore, Dr. Bhattacharya sought to reassure lawmakers regarding the integrity of scientific inquiry, promising to insulate the research enterprise from political influence—a growing concern among both parties.
The "Forward-Funding" Controversy
A significant point of friction surfaced during the testimony, led by Ranking Member Rosa DeLauro (D-CT). Representative DeLauro challenged the administration’s practice of "forward-funding"—the allocation of multi-year payments for research grants at the onset of a project.
According to DeLauro, this practice has had a deleterious effect on the broader research ecosystem, leading to approximately 2,000 fewer grants in 2025 and resulting in an acceptance rate of less than 10% for NCI research applications. In response to these concerns, the final FY 2026 funding bill included strict provisions to limit forward-funding to 2025 levels. METAvivor is closely monitoring this issue, as any sudden policy shift in how the NCI manages grant cycles could have a direct impact on the volume and speed of breast cancer research initiatives.
GroundSwell 2026: A Grassroots Success Story
The third annual GroundSwell Virtual Advocacy event, which launched on February 23, concluded its extended session in mid-March. Originally slated to wrap up on March 6, the event was extended by two weeks to accommodate the high volume of meetings scheduled by participants.
Engagement Metrics
More than 100 advocates participated in this year’s event, marking a significant milestone for METAvivor. The virtual format allowed for a broader geographic spread, enabling patients and caregivers from across the country to interface directly with their congressional representatives.
The organization is currently processing post-meeting survey data. This feedback is vital, as it will shape the strategy for the fall "Stampede" event and the development of the 2027 GroundSwell programming. The goal is to refine the "advocate experience," ensuring that those sharing their personal stories of living with MBC are equipped with the best possible data and talking points to sway legislative outcomes.
Strategic Initiatives: SEER and Digital Empowerment
Beyond the immediate budget battles, METAvivor is investing in long-term structural improvements to the way cancer data is collected and how advocacy is conducted.
Modernizing the SEER Registry
METAvivor has launched a collaborative effort with the North American Association of Central Cancer Registries (NAACCR) and the National Cancer Registrar’s Association (NCRA). The goal is to better understand the National Cancer Institute’s SEER (Surveillance, Epidemiology, and End Results) Cancer Registry and the CDC’s National Program for Cancer Registries (NCPR).
The collaboration is designed to ensure that the data collected by these registries is not only more robust but also more inclusive of metastatic breast cancer patients. By working with registry experts, METAvivor hopes to advocate for modernization efforts that provide a more accurate picture of the MBC population, which is essential for informed policy-making and clinical research.
Launching VoterVoice
To bolster its grassroots capacity, METAvivor is rolling out VoterVoice, a state-of-the-art e-advocacy platform. Following Board approval earlier this month, the system is being prepared for a full launch in April.
VoterVoice is expected to be a game-changer for the METAvivor community. It provides a centralized hub where advocates can:
- Identify Congressional Representatives: Automatically match users with their specific federal legislators.
- Streamline Communication: Access pre-drafted, staff-approved letters that can be sent with a single click, or personalized with the advocate’s unique story.
- Data-Driven Engagement: Provide the organization with high-level analytics, such as identifying key congressional districts where METAvivor has a strong presence, which helps in focusing "grasstops" lobbying efforts.
Looking Ahead: The April Agenda
As METAvivor transitions into April, the focus remains squarely on sustained momentum. The upcoming month’s priorities are threefold:
- Legislative Pressure: Continuing to lobby for the FY 2027 appropriations, with a heavy emphasis on the $150 million BCRP funding request and the introduction of the Cancer Drug Parity Act in the Senate.
- Infrastructure: Finalizing the launch of VoterVoice and training advocates on how to utilize the tool to its full potential.
- Data Strategy: Deepening the partnership with NAACCR and NCRA to ensure that the registry data landscape evolves to meet the needs of the MBC community.
The road ahead is complex, but for the METAvivor team and their network of advocates, the objective remains clear: to ensure that the voices of those living with metastatic breast cancer are heard, prioritized, and acted upon in the halls of Congress. Through a combination of rigorous policy oversight, technological adoption, and unwavering personal testimony, METAvivor is positioning itself for a pivotal year of advocacy.
About the Author
